Fra Chemometec:
Preliminary revenue figures for the 2023/24 financial year
ANNOUNCEMENT NO. 270
2 July 2024
Preliminary revenue figures for the 2023/24 financial year
In the fourth quarter of the 2023/24 financial year, ChemoMetec’s revenue was DKK 109.2 million, corresponding to a growth of 13.5% from the year-earlier period.
The revenue for the 2023/24 financial year was DKK 407.4 million against DKK 442.3 million the previous year, corresponding to a decrease of 7.9%. The revenue in 2023/24 is thus in line with the latest disclosed guidance for the revenue of DKK 400-415 million, disclosed on 8 May 2024.
In the fourth quarter of 2023/24, ChemoMetec sold XcytoMatic instruments for DKK 4.4 million, an increase of 69% compared to the third quarter of the financial year.
Revenue by product group
DKKm | Q4 2023/24 | Q4 2022/23 | Q3 2023/24 | 2023/24 | 2022/23 |
Instruments | 32.2 | 32.0 | 23.1 | 117.1 | 179.0 |
Consumables | 50.4 | 41.8 | 52.6 | 192.5 | 174.4 |
Services | 25.4 | 21.4 | 22.1 | 93.5 | 83.0 |
Other | 1.2 | 1.0 | 1.1 | 4.3 | 5.9 |
Total revenue | 109.2 | 96.2 | 98.9 | 407.4 | 442.3 |
In the annual report for 2023/24, which will be published on 11 September 2024, the development in revenue will be further described.
The previously announced guidance for EBITDA in 2023/24 (DKK 185-200 million) is maintained.